XJPX9341
Market cap147mUSD
Jan 16, Last price
1,311.00JPY
1D
-0.98%
1Q
-28.94%
IPO
-27.33%
Name
Genova Inc
Chart & Performance
P/E
13.37
P/S
2.66
EPS
98.03
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
8.68b
+33.32%
Net income
1.73b
+37.04%
CFO
1.82b
+51.45%
Dividend
Mar 28, 20250 JPY/sh
Profile
GENOVA, Inc. engages in the medical platform and smart clinic businesses in Japan. It offers Medical Doc, a platform that distributes articles for medical institutions, patient experience articles, treatment videos, and medical-related articles. It also provides Smart Clinic, an online medical treatment and consultation service, which offers medical treatment at home or work for users without going to a hospital. In addition, the company offers NOMOCa-Stand, a smart and simple automatic payment and reception machine; NOMOCa-Regi, a self-pay machine dedicated to the clinic; and CLINIC BOT, an AI Chatbot System. The company was founded in 2005 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | |
| Income | ||||
Revenues | 8,683,488 33.32% | 6,513,466 35.64% | 4,802,057 27.42% | |
Cost of revenue | 6,427,297 | 4,807,556 | 1,338,114 | |
Unusual Expense (Income) | ||||
NOPBT | 2,256,191 | 1,705,910 | 3,463,943 | |
NOPBT Margin | 25.98% | 26.19% | 72.13% | |
Operating Taxes | 612,660 | 454,508 | 370,608 | |
Tax Rate | 27.15% | 26.64% | 10.70% | |
NOPAT | 1,643,531 | 1,251,402 | 3,093,335 | |
Net income | 1,726,894 37.04% | 1,260,112 83.62% | 686,270 9.04% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 24,419 | 1,291,983 | 29,800 | |
BB yield | -0.10% | -5.41% | ||
| Debt | ||||
Debt current | 356,945 | 21,306 | 96,756 | |
Long-term debt | 20,835 | 9,119 | 74,523 | |
Deferred revenue | ||||
Other long-term liabilities | 15,358 | 26,405 | 29,060 | |
Net debt | (5,588,491) | (4,023,110) | (1,664,774) | |
| Cash flow | ||||
Cash from operating activities | 1,822,117 | 1,203,079 | 623,774 | |
CAPEX | (57,030) | (93,392) | (115,302) | |
Cash from investing activities | (94,238) | (113,450) | (179,061) | |
Cash from financing activities | 376,818 | 1,131,226 | 59,885 | |
FCF | 1,057,598 | 1,206,491 | 3,011,551 | |
| Balance | ||||
Cash | 5,965,579 | 3,860,506 | 1,654,504 | |
Long term investments | 692 | 193,029 | 181,549 | |
Excess cash | 5,532,097 | 3,727,862 | 1,595,950 | |
Stockholders' equity | 5,104,364 | 3,387,193 | 1,476,933 | |
Invested Capital | 1,326,063 | 253,171 | (206,271) | |
ROIC | 208.14% | 5,336.47% | ||
ROCE | 35.09% | 46.86% | 272.61% | |
| EV | ||||
Common stock shares outstanding | 17,894 | 17,245 | 15,972 | |
Price | 1,421.00 2.67% | 1,384.00 | ||
Market cap | 25,426,901 6.53% | 23,867,456 | ||
EV | 19,838,410 | 19,852,838 | ||
EBITDA | 2,329,902 | 1,760,169 | 3,502,520 | |
EV/EBITDA | 8.51 | 11.28 | ||
Interest | 555 | 1,521 | 2,151 | |
Interest/NOPBT | 0.02% | 0.09% | 0.06% | |